The mission of CasInvent Pharma is to bring new therapeutic options for the treatment of selected leukemias to market. We are developing highly selective small molecule inhibitors of casein kinase I (CK1), and our main development program is focused on the identification of new drugs for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). CasInvent Pharma was established in 2020 as a spin-off company of Masaryk University in cooperation with the investment partner i&i Prague.